Business Description
Vir Biotechnology Inc
NAICS : 325412
SIC : 2834
ISIN : US92764N1028
Total Employee Number:
367Compare
Compare
Traded in other countries / regions
VIR.USAVIR.Mexico Index Membership
Russell 2000Russell 3000 IPO Date
2019-10-11Description
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.71 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.35 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.71 | |||||
Beneish M-Score | 15.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -65.5 | |||||
3-Year Book Growth Rate | -29.4 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 82.38 | |||||
9-Day RSI | 65.84 | |||||
14-Day RSI | 57.74 | |||||
3-1 Month Momentum % | 7.53 | |||||
6-1 Month Momentum % | 20.43 | |||||
12-1 Month Momentum % | 110.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.04 | |||||
Quick Ratio | 6.04 | |||||
Cash Ratio | 5.61 | |||||
Days Payable | 253470.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.5 | |||||
Shareholder Yield % | -14.61 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 100 | |||||
Operating Margin % | -92.6 | |||||
Net Margin % | -83.18 | |||||
EBITDA Margin % | -88.79 | |||||
FCF Margin % | -67.28 | |||||
OCF Margin % | -66.92 | |||||
ROE % | -29.24 | |||||
ROA % | -23.07 | |||||
ROIC % | -53.02 | |||||
3-Year ROIIC % | -538.42 | |||||
ROC (Joel Greenblatt) % | -225.1 | |||||
ROCE % | -27.94 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.09 | |||||
PB Ratio | 1.63 | |||||
Price-to-Tangible-Book | 1.68 | |||||
EV-to-EBIT | -4.16 | |||||
EV-to-EBITDA | -4.34 | |||||
EV-to-Forward-EBITDA | -3.5 | |||||
EV-to-Revenue | 3.85 | |||||
EV-to-Forward-Revenue | 4.44 | |||||
EV-to-FCF | -5.73 | |||||
Price-to-GF-Value | 0.22 | |||||
Price-to-Projected-FCF | 4.5 | |||||
| Price-to-Net-Current-Asset-Value | 4.7 | |||||
| Price-to-Net-Cash | 5.34 | |||||
Earnings Yield (Greenblatt) % | -24.04 | |||||
FCF Yield % | -12.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VIR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vir Biotechnology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 302.589 | ||
| EPS (TTM) ($) | -1.86 | ||
| Beta | 1.9546 | ||
| 3-Year Sharpe Ratio | -0.12 | ||
| 3-Year Sortino Ratio | -0.18 | ||
| Volatility % | 41.71 | ||
| 14-Day RSI | 57.74 | ||
| 14-Day ATR ($) | 0.403668 | ||
| 20-Day SMA ($) | 8.99525 | ||
| 12-1 Month Momentum % | 110.49 | ||
| 52-Week Range ($) | 4.25 - 11.66 | ||
| Shares Outstanding (Mil) | 169.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vir Biotechnology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vir Biotechnology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 79 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 78 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | 9.17 (+1.66%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 9.17 (+1.66%) | ||
| General meeting for 2026 | 2026-05-26 09:00 | 9.19 (+1.32%) | ||
| Guidance call for 2026 | 2026-05-12 16:20 | 9.29 (+1.53%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 16:30 | 10.01 (-3.10%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 10.01 (-3.10%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 13:40 | 9.80 (+3.81%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 15:10 | 9.09 (-2.15%) |
Show
Entries
Vir Biotechnology Inc Frequently Asked Questions
What is Vir Biotechnology Inc(VIR)'s stock price today?
The current price of VIR is $9.50. The 52 week high of VIR is $11.66 and 52 week low is $4.25.
When is next earnings date of Vir Biotechnology Inc(VIR)?
The next earnings date of Vir Biotechnology Inc(VIR) is 2026-11-05 Est..
Does Vir Biotechnology Inc(VIR) pay dividends? If so, how much?
Vir Biotechnology Inc(VIR) does not pay dividend.
Guru Commentaries on NAS:VIR
No articles.
Press Release
Articles on Vir Biotechnology Inc
VIR SWOT Analysis: Financial Resilience Amidst Clinical Challenges Revealed in 10-Q Filing
Aug 06, 2026
Headlines
See More- 1
Aug 06, 2026
Vir outlines ECLIPSE 1 top-line in Q4 2026 while projecting cash runway into the second half of 2028
Seeking Alpha • 3:20am
Aug 05, 2026
Vir Biotechnology Non-GAAP EPS of $0.47 misses by $0.43, revenue of $238.94M beats by $16.37M
Seeking Alpha • 4:17pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers